WO2004067575A1 - Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters - Google Patents

Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters Download PDF

Info

Publication number
WO2004067575A1
WO2004067575A1 PCT/IB2003/000321 IB0300321W WO2004067575A1 WO 2004067575 A1 WO2004067575 A1 WO 2004067575A1 IB 0300321 W IB0300321 W IB 0300321W WO 2004067575 A1 WO2004067575 A1 WO 2004067575A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
process according
hyaluronic acid
gel
bi
according
Prior art date
Application number
PCT/IB2003/000321
Other languages
French (fr)
Inventor
Luigi Fratini
Maurizio Meldoli
Original Assignee
Biosphere S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use

Abstract

Soluble and bio-compatible gels consisting of hyaluronic acid cross-linked with bi­functional L-amino acids or L-amino esters, or mixture thereof are described; also described is a process for their preparation and their use in pharmaceutical, cosmetic and medical-surgical field.

Description

WATER SOLUBLE AND BIOCOMPATIBLE GELS OF HYALURONIC ACID CROSS-LINKED WITH BIFUNCTIONAL L-AMINOACIDS OR L-AMINOESTERS

Field of the invention

The present invention refers to soluble, bio-compatible gels consisting of hyaluronic acid cross-linked with bi-functional L-aminoacids or L-aminoesters, or mixtures thereof, to a process for their preparation and to their use in the pharmaceutical, cosmetic surgical and medical fields.

State of the art

Hyaluronic acid is a mucopolysaccharide consisting of alternated units of D- glucuronic acid and N-acetyl-glucosamine, bound together by β 1-3 and β-4 bindings.

Hyaluronic acid is found in nature in the synovial liquid of articular joints, in the vitreous humour of eyes, in the umbilical cordon and in the connective tissues.

Hyaluronic acid can be obtained by extraction from animal tissues like cockscombs or umbilical cordons, or can be recovered from the fermenting broth of specific Streptococci.

The development of biotechnology allowed the optimisation and improvement of the last described method of production of hyaluronic acid which is nowadays the one considered the most simple and rewarding. The applications of hyaluronic acid, in surgery, pharmacology and in general in biomedicine, are widely described in literature, see for example: Balazs et al.

"Hyaluronan Biomaterials: Medical Applications", Handbook of Biomaterials and

Applications, Ed. D Wise et al, 1995, 2719-2741; US - 5,559,104, 1996; Pape,

Balazs, Ophthalmology, 87, No 7, 1980; Iwata, Clin. Orthop., 289, 285-291; 1993; US 5,128,326; US - 4,500,676; US - 5,840,046; US - 5,795,584; US -

6,010,692; US - 5,658,331.

Since the important role played by hyaluronic acid in the human body is due to the peculiar viscoelastic, lubricant and hydrophilic characteristics of its aqueous solutions the searchers are studying and preparing hyaluronic acid derivatives wherein such properties are changed in order to obtain compounds for various uses.

A wide literature report various products derived from the cross-linking of hyaluronic acid with, for example, formaldheyde (Balazs, US 4,713,448, 1987), divinyl sulphone (Balazs, US 4,582,865, 1986), aziridine, alcohols (Delia Valle, US 4,851 ,521, 1989) and mono-functional amino acids (Hamilton, US 4,937,270, 1990). In particular Miller et al., US 5,760,200, 1998 described meythods for the preparation of insoluble derivatives of hyaluronic acids, for example with L-lysine ethylester, in the presence of carbodiimide soluble in water, the reaction was performed in the present of a high excess of activating agent and amino acid in order to obtain an insoluble gel. Moreover in WO 01/58961, in the name of the present Applicant, derivatives of hyaluronic acid cross-linked with bi-functional L- amino acids and L-amino esters, and process for their preparation both in water and in organic solvents are described, however the therein described products, in spite of their quality, should be improved in respect of their purity, viscolelastic and biocompatible properties in view of their possible pharmacological, medical or surgical use.

It is therefore evident, in view of the above said, the importance of making available new compounds capable of widening and improving the use of hyaluronic acid in the known or in new fields. Detailed description of the invention The present invention allows to overcome the above said problem by making available gels soluble in water and bio-compatible prepared by cross-linking hyaluronic acid with bi-functional L-aminoacids or L-aminoesters or their mixtures. The characteristics of the compounds according to the invention make them ideal products for use in various fields from pharmaceutical to medical. The product, in the form of film or gel, can for example be used as anti-adherent material in surgery (in abdomen, spinal surgery etc); in this case the material forms a barrier separating the damaged tissues and is absorbed after a time which allows the formation of the new tissues. The products according to the present invention can be also used as substrate for tissue engineering (derma, epidermis tissue, bones, fat cells, etc.) and can be used in ophthalmology, dermatology, in the osteoartritis field etc. The compounds according to the invention can be prepared in water or in a mixture water/organic solvents as DMF or DMSO depending on their use. In both cases the reaction is carried out in two subsequent steps: firstly the hyaluronic acid is activated and thereafter the binding between hyaluronic acid a cross-linking agent is performed. The activation of hyaluronic acid takes place in the presence of a carbodiimide soluble in water according to known processes (see for example Tomihata, J. Biomed. Mater. Res., 1997, 37(2), 243-251; Danishefsky, Carbohydrate Res., 1971, 16, 199-205). Among the various carbodiimides soluble in water the N-3-dimethylamino-propylethylcarbodiimide hydrochloride is particularly preferred. According to the present invention the cross-linking agents are bi-functional α L- amino acids, i.e. having a second functional group besides the amino acid group, or their esters or mixtures thereof. Particularly preferred are L-lysine, L-serine, L- lysine ethylester di-hydrochloride, L-lysine methylester di-hydrochloride, L-serine methylester hydrochloride, L-serine ethylester hydrochloride or mixtures thereof. The use of amino esters instead of amino acids allows the protection of the carboxylic functions of the amino acids in respect of their possible activation and their involvement in secondary reactions.

The reaction is carried out in a reactor equipped with a stirring system and a temperature controller. The hyaluronic acid sodium salt is dissolved in water in a concentration comprised between 0.5 and 2.5% according to the desired characteristics of the final product, the preferred concentration is 1 - 1.5%. The reaction temperature is one of the essential condition for obtaining the products of the invention and it must be comprised between 0°C and 25°C, preferably between 0°C and 10°C. The pH is brought at 3 - 6, preferably 4-5, for example by adding diluted HCl.

Another essential factor for obtaining the products according to the invention it is the ratio: activating agent/hyaluronic acid sodium salt; the activating agent must be added in quantities comprised between 0.05 - 0.5 equivalents for equivalent of monomer unit of hyaluronic acid, preferably between 0.1 and 0.2 equivalents. If higher quantities of activating agent are used irreversible binding between hyaluronic acid and activating agent takes place instead of the wanted binding hyaluronic acid/cross-linking agent which causes the formation of undesired products which are insoluble or partially insoluble in water and having bio- compatibility and purity characteristics which are different from those of the presently described products. Finally the cross-linking agent is added in quantities comprised between 0.1 - 1 equivalents for equivalent of monomer unit of starting hyaluronic acid.

After the above said the reaction mixture is kept at the fixed temperature and under stirring for 15 minutes - 4 hours, preferably 30 minutes - 2 hours. A solution of NaCl 1 M is added and a buffer solution at pH 7 - 8 (preferably 7.5) then the mixture is purified according to known techniques as dialysis and/or diafiltration on ultrafiltration membrane and/or precipitation with an organic solvent and/or evaporation under vacuum and/or freeze drying. The preferred methods are diafiltration on membrane having a cutoff of 30 KDa and freeze drying. The solid product can be solved in water or in physiologic solution in various concentrations in order to obtain viscous solutions or transparent gels, it is also possible to obtain thin films, membranes according to the wanted use. The product can be sterilised for example by filtration at 0.2 μ. The reciprocal quantities hyaluronic acid/activating agent/cross-linking agent have an effect on the cross-linking grade and therefore they will be chosen according to the wanted viscoelastic properties. Obviously the final characteristics will also be a consequence of the hyaluronic acid used as starting product.

In fact, the other condition being unvaried, the use of a hyaluronic acid having higher molecular weight will result in a liquid more viscous and compact compared to the one obtained with a hyaluronic acid having lower molecular weight. Preferably according to the invention hyaluronic acid having a molecular weight comprised between 100.000 and 2.000.000 is used and the final products will have a molecular weight comprised between 200.000 and 2.500.000. The final products have a cross-linking degree of 2 - 40%. The invention will be better understood in view of the following examples. EXAMPLE 1

1 g of hyaluronic acid sodium salt (MW 1.550.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.048 g (0.1 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.31 g (0.5 eq) of L-lysine ethylesterdi- hydrochloride are added. After 1 hours 10 ml of NaCl solution 1 M and 10 ml of buffer solution at pH 7.5 are added, the gel is diafiltered with 10 volumes of demineralised water on a membrane with cutoff 30 KDa and finally freeze-dried. EXAMPLE 2

1 g of hyaluronic acid sodium salt (MW 1.550.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.096 g (0.2 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.31 g (0.5 eq) of L-lysine ethylesterdi- hydrochloride are added.

After 1 hours 10 ml of NaCl solution 1 M and 10 ml of buffer solution at pH 7.5 are added; the gel is diafiltered with 10 volumes of demineralised water on a membrane with cutoff 30 KDa and finally freeze-dried. EXAMPLE 3

1 g of hyaluronic acid sodium salt (MW 750.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.048 g (0.1 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.20 g (0.5 eq) of L-serine methylester hydrochloride are added.

After 1 hours 10 ml of NaCl solution 1 M and 10 ml of buffer solution at pH 7.5 are added, the gel is diafiltered with 10 volumes of demineralised water on a membrane with cutoff 30 KDa and finally freeze-dried. EXAMPLE 4

1 g of hyaluronic acid sodium salt (MW 750.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.096 g (0.2 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.20 g (0.5 eq) of L-serine methylester hydrochloride are added.

After 1 hours 10 ml of NaCl solution 1 M and 10 ml of buffer solution at pH 7.5 are added, the gel is diafiltered with 10 volumes of demineralised water on a membrane with cutoff 30 KDa and finally freeze-dried.

EXAMPLE 5

1 g of hyaluronic acid sodium salt (MW 1.600.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.048 g (0.1 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.18 g (0.5 eq) of L-lysine are added.

After 1 hours 10 ml of NaCl solution 1M and 10 ml of buffer solution at pH 7.5 are added; the gel is diafiltered with 10 volumes of demineralised water on a membrane with cutoff 30 KDa and finally freeze-dried. EXAMPLE 6

The solid obtained in Example 1 is dissolved in water in a concentration of 3-4g/l and filtered, under sterile condition, at 0.2 microns.

The filtered gel is sterile and has a content of endotoxines lower than 0.2

EU/mg(ss). The physico-chemical characterisation showed a cross-linking degree of 10% a loss by drying of 18-20% and the following 1 H-NMR signals (solvent D20):

1.2 ppm (t, 3H, J = 10.6 Hz, CH3-CH2O-Lys)

1.4 ppm (m, 2H, Ch δ Lys)

1.6 ppm (m, 2H, CH? γ Lys) 1.7-1.9 ppm (m, 2H, CH2 β Lys)

1.9-2.0 ppm (m, 3H, CH3-CONH hyaluronic acid)

2.9 ppm (t, 2H, J = 11.2 Hz, CH2 ε Lys)

3.0-3.9 ppm (m, CHOH hyaluronic acid)

4.0 ppm (t, 1 H, J = 9.6 Hz, CH α Lys) 4.2 ppm (q, 2H, J = 10.6 Hz, CHs-ChbO-Lys)

Claims

1. A process for the preparation of soluble, biocompatible gels consisting of hyaluronic acid cross-linked with bi-functional cross-linking agents wherein:
- the hyaluronic acid is solved in water at a concentration of 0.5 2.5% (w/w) and at a temperature of 0° - 25°C and the solution pH is brought at 3-6; the solution is added with bi-functional cross-linking agents, in a quantity comprised between 0.1 - 1 equivalent for each equivalent of monomer unit of hyaluronic acid, and an activating agent, in a quantity comprised between 0.05 - 0.5 equivalents for each equivalent of monomer unit of hyaluronic acid; - the solution is stirred for 15 minutes - 4 hours;
- the solution is added with a solution of NaCl 1 M and a buffer solution at pH 7 - 8;
- the formed gel is collected and purified according to known techniques.
2. Process according to claim 1 wherein the bi-functional cross-linking agents are L-amino acids and/or L-amino esters or mixtures thereof.
3. Process according to claim 2 wherein the bi-functional cross-linking agents are: L-lysine, L-serine, L-lysine ethylester dihydrochloride, L-lysine methylester dihydrochloride, L-serine ethylester hydrochloride, L-serine methylester hydrochloride or mixtures thereof.
4. Process according to Claims 1 - 3 wherein the reaction temperature is comprised between 0 - 10°C.
5. Process according to claim 4 wherein the reaction pH is comprised between 3 - 6.
6. Process according to claim 5, wherein the reaction pH is comprised between 4 - 5.
7. Process according to claims 1-6, wherein the activating agent is a carbodiimide soluble in water.
8. Process according to claim 7, wherein the activating agent is N-3- dimethylamino-propylethylcarbodiimide hydrochloride.
9. Process according to claims 1-8, wherein the activating agent is added in a quantity comprised between 0.1 - 0.2 equivalents for each equivalent of monomer unit of hyaluronic acid.
10. Process according to claims 1-9, wherein the reaction time is comprised between 30 minutes and 2 hours.
11. Process according to claims 1-10, wherein the finally obtained gel is added with a solution of NaCl 1 M and a buffer solution at pH 7.5
12. Process according to claims 1-11 , wherein the gel is purified by dialysis and/or diafiltration on ultrafiltering membrane and/or precipitation with an organic solvent and/or evaporation under vacuum and/or freeze-drying.
13. Process according to claim 12, wherein the gel is purified by diafiltration on a membrane with cutoff 30 KDa and freeze-dried.
14. Process according to claims 1- 13 wherein the purified gel is sterilised by filtration at 0.2 microns.
15. Process according to claims 1-14 wherein the hyaluronic acid has a MW comprised between 100.000 and 2.000.000.
16. Soluble and bio-compatible gels consisting of hyaluronic acid cross-linked with bi-functional cross-linkants, obtained through a process according to claims 1 - 14.
17. Gel according to claim 16 having a cross-linking degree of 2-40%.
18. Gel according to claims 16 and 17 having a MW of 200.000 - 2.500.000.
19. Use of a gel according to claims 16-18 as anti-adherent material in surgical field.
20. Use of a gel according to claims 16 - 18 as a substrate for tissue engineering (derma, epidermis tissue, bones, fat cells).
21. Use of a gel according to claims 16 - 18 as a product for applications in ophthalmology, dermatology, or in the field of osteoartritis.
PCT/IB2003/000321 2003-01-31 2003-01-31 Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters WO2004067575A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/000321 WO2004067575A1 (en) 2003-01-31 2003-01-31 Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2003/000321 WO2004067575A1 (en) 2003-01-31 2003-01-31 Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters
EP20030815561 EP1592715A1 (en) 2003-01-31 2003-01-31 Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters
AU2003303820A AU2003303820A1 (en) 2003-01-31 2003-01-31 Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters

Publications (1)

Publication Number Publication Date
WO2004067575A1 true true WO2004067575A1 (en) 2004-08-12

Family

ID=32800540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000321 WO2004067575A1 (en) 2003-01-31 2003-01-31 Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters

Country Status (2)

Country Link
EP (1) EP1592715A1 (en)
WO (1) WO2004067575A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011148116A3 (en) * 2010-05-27 2012-05-10 Centre National De La Recherche Scientifique - Cnrs Modified hyaluronic acid, method for manufacturing same and uses thereof
US20130096081A1 (en) * 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US8481080B2 (en) 2004-11-24 2013-07-09 Novozymes Biopolymer A/S Method of cross-linking hyaluronic acid with divinulsulfone
US20140315828A1 (en) * 2013-04-22 2014-10-23 Allergan, Inc. Cross-linked silk-hyaluronic acid compositions
US9109051B2 (en) 2007-12-19 2015-08-18 Evonik Goldschmidt Gmbh Crosslinked hyaluronic acid in emulsion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058961A1 (en) * 2000-02-08 2001-08-16 S.F.I.R. S.P.A. Societa' Fondiaria Industriale Romagnola Gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters or mixtures thereof
EP1229050A2 (en) * 1991-05-20 2002-08-07 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229050A2 (en) * 1991-05-20 2002-08-07 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
WO2001058961A1 (en) * 2000-02-08 2001-08-16 S.F.I.R. S.P.A. Societa' Fondiaria Industriale Romagnola Gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters or mixtures thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481080B2 (en) 2004-11-24 2013-07-09 Novozymes Biopolymer A/S Method of cross-linking hyaluronic acid with divinulsulfone
US9109051B2 (en) 2007-12-19 2015-08-18 Evonik Goldschmidt Gmbh Crosslinked hyaluronic acid in emulsion
WO2011148116A3 (en) * 2010-05-27 2012-05-10 Centre National De La Recherche Scientifique - Cnrs Modified hyaluronic acid, method for manufacturing same and uses thereof
US20130096081A1 (en) * 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US20140315828A1 (en) * 2013-04-22 2014-10-23 Allergan, Inc. Cross-linked silk-hyaluronic acid compositions

Also Published As

Publication number Publication date Type
EP1592715A1 (en) 2005-11-09 application

Similar Documents

Publication Publication Date Title
US6734298B1 (en) Cross-linking process of carboxylated polysaccharides
US6982298B2 (en) Hydroxyphenyl cross-linked macromolecular network and applications thereof
US20020049281A1 (en) Process for cross-linking hyaluronic acid to polymers
US20080193538A1 (en) Hyaluronic Acid Compound, Hydrogel Thereof and Joint Treating Material
US20100316715A1 (en) Chitosan composition
US5616568A (en) Functionalized derivatives of hyaluronic acid
US20050281880A1 (en) Methods for making injectable polymer hydrogels
US7125860B1 (en) Cross-linked derivatives of hyaluronic acid
US20120190644A1 (en) Viscoelastic gels as novel fillers
US20050119219A1 (en) Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
US6521223B1 (en) Single phase gels for the prevention of adhesions
EP0640647A2 (en) Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery
US20050142152A1 (en) Polymeric materials, their preparation and use
WO2010029344A2 (en) Hyaluronic acid cryogel
US4937270A (en) Water insoluble derivatives of hyaluronic acid
EP1095064B1 (en) Amides of hyaluronic acid and the derivatives thereof and a process for their preparation
US5527893A (en) Water insoluble derivatives of polyanionic polysaccharides
US20100291171A1 (en) Hyaluronic acid derivatives obtained via "click chemistry" crosslinking
EP1419792A1 (en) Glycosaminoglycan-polycation complex crosslinked by polyfunctional crosslinking agent and process for producing the same
US5017229A (en) Water insoluble derivatives of hyaluronic acid
US6030958A (en) Water insoluble derivatives of hyaluronic acid
US6831172B1 (en) Cross-linked hyaluronic acids and medical uses thereof
US5760200A (en) Water insoluble derivatives of polyanionic polysaccharides
US6235726B1 (en) Water insoluble derivatives of polyanionic polysaccharides
WO2005113608A1 (en) Method of covalently linking hyaluronan and chitosan

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003815561

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003815561

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP